Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid

Executive Summary

Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.


Related Content

Perrigo Primed For M&A; Sheds Elan Asset
Perrigo Primed For M&A; Sheds Elan Asset
2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A
Biopharma Dealmaking Quarterly Statistics, Q3 2013
Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree
Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott
Regional Firms Must Compete With Multinationals At Home And Away
It's Fusion As Jazz Pharmaceuticals, Azur Pharma Reach Merger Agreement
Elan Unit’s Acquisition Brings Diversification, Cash Flow, To Alkermes
Tax Benefits Highlight Announced Merger Of Valeant And Biovail


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts